Pfizer Launches First Clinical Trial Of A Pill To Treat COVID-19 That Prevents The Virus From Making Copies Of Itself

Pfizer Launches First Clinical Trial Of A Pill To Treat COVID-19 That Prevents The Virus From Making Copies Of Itself

Pfizer has launched early-stage human trials of an experimental oral drug that could be prescribed to patients at the first sign of infection with COVID-19.  The drug maker, which developed the first authorized COVID-19 vaccine in the U.S. with Germany’s BioNTech SE, said the antiviral candidate showed potent activity against the virus in lab studies.  Pfizer’s candidate, which is called PF-07321332, belongs to a class of drugs known as protease inhibitors.  The pill would work by inhibiting an enzyme that the coronavirus uses to make copies of itself inside human cells.

Photo Credit: Pfizer

 

After 9 Podcast - 91.5 The Beat